---
title: "GSK.UK (GSK.UK) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GSK.UK/news.md"
symbol: "GSK.UK"
name: "GSK.UK"
parent: "https://longbridge.com/en/quote/GSK.UK.md"
datetime: "2026-05-20T08:58:13.917Z"
locales:
  - [en](https://longbridge.com/en/quote/GSK.UK/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GSK.UK/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GSK.UK/news.md)
---

# GSK.UK (GSK.UK) — Related News

### [Notable ETF Inflow Detected - FENI, BTI, AER, GSK](https://longbridge.com/en/news/286935809.md)
*2026-05-19T15:00:48.000Z*
> The Fidelity Enhanced International ETF (FENI) has seen a notable inflow of approximately $311.7 million, marking a 3.4%

### [GlaxoSmithKline's RSV vaccine approved in Japan for expanded eligible population](https://longbridge.com/en/news/286724118.md)
*2026-05-18T06:31:25.000Z*
> On May 18th, GlaxoSmithKline plc announced that Japan's Ministry of Health, Labour and Welfare has officially approved t

### [GSK: Japan's MHLW Expands Eligible Population For Arexvy](https://longbridge.com/en/news/286723820.md)
*2026-05-18T06:27:26.000Z*
> GSK plc announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for its RSV v

### [The billion-dollar ADC anti-cancer drug sector welcomes new players, and pharmaceutical companies look forward to diversified payment options to enhance accessibility](https://longbridge.com/en/news/286547393.md)
*2026-05-15T10:18:27.000Z*
> GlaxoSmithKline plc (GSK) has launched the only approved anti-B-cell maturation antigen (BCMA) ADC drug for the treatmen

### [GSK executives acquire shares under company reward plan](https://longbridge.com/en/news/286434027.md)
*2026-05-14T14:33:05.000Z*
> GSK executives, including the President of Europe and CFO, acquired shares under the company's Share Reward Plan on May 

### [GSK and SBP Group team up to advance bepirovirsen launch in China](https://longbridge.com/en/news/286073604.md)
*2026-05-12T09:41:54.000Z*
> GSK has partnered with SBP Group to launch bepirovirsen in China, leveraging CTTQ's extensive network of over 5,000 medi

### [Understanding the Market | SBP GROUP rose over 3% as Goldman Sachs indicated that the introduction of bepirovirsen therapy is expected to upgrade the company's hepatitis product portfolio](https://longbridge.com/en/news/286041040.md)
*2026-05-12T05:48:04.000Z*
> China National Pharmaceutical Group's stock price rose over 3%, up 2.65% at the time of publication, reported at HKD 5.8

### [<![CDATA[Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen]]>](https://longbridge.com/en/news/285984513.md)
*2026-05-11T18:58:40.000Z*
> GSK has partnered with Sino Biopharmaceutical's CTTQ to launch bepirovirsen in China, currently under regulatory review 

### [GSK China Hepatitis B Push Raises Questions For Valuation And Dividend Risks](https://longbridge.com/en/news/285980824.md)
*2026-05-11T18:11:05.000Z*
> GSK has partnered with Sino Biopharmaceutical to launch bepirovirsen, a potential hepatitis B treatment in China, target